Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Short Interest Up 17.7% in April

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Get Free Report) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 2,330,000 shares, a growth of 17.7% from the April 15th total of 1,980,000 shares. Based on an average daily volume of 378,800 shares, the short-interest ratio is currently 6.2 days.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company's stock valued at $11,325,000 after acquiring an additional 82,113 shares in the last quarter. Sanders Morris Harris LLC bought a new stake in shares of Actinium Pharmaceuticals in the 1st quarter worth $78,000. Creative Financial Designs Inc. ADV raised its stake in shares of Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company's stock worth $101,000 after purchasing an additional 3,175 shares during the last quarter. Finally, Brandywine Global Investment Management LLC bought a new position in shares of Actinium Pharmaceuticals during the third quarter valued at $1,033,000. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:ATNM traded up $0.10 during trading on Thursday, hitting $9.83. The stock had a trading volume of 236,891 shares, compared to its average volume of 327,277. The firm has a market capitalization of $292.74 million, a P/E ratio of -5.75 and a beta of 0.08. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $10.24.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) last issued its quarterly earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.11. On average, equities analysts forecast that Actinium Pharmaceuticals will post -1.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ATNM. Maxim Group upped their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, March 19th. Stephens assumed coverage on Actinium Pharmaceuticals in a report on Tuesday. They issued an "overweight" rating and a $25.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, April 29th. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. Finally, StockNews.com upgraded shares of Actinium Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, May 5th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Actinium Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $25.60.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.